Metabolic reprogramming is not only an emerging hallmark of cancer, but also an essential regulator of cancer cell adaptation to the microenvironment. Metabolic imaging targeting metabolic signatures has been widely used for breast cancer diagnosis. However, limited implications have been explored for monitoring breast cancer therapy response, although metabolic plasticity is notably associated with therapy resistance. In this review, we focus on the metabolic alterations upon breast cancer therapy and their potential for evaluating breast cancer therapeutic responses. We summarize the metabolic network and regulatory changes upon breast cancer therapy in terms of cancer pathological and genetic differences and discuss the implications of metabolic imaging with various probes in selecting target beneficiaries for precision treatment.

代谢重编程不仅是癌症的新兴标志，也是癌细胞适应微环境的重要调节因子。针对代谢特征的代谢成像已广泛用于乳腺癌诊断。然而，尽管代谢可塑性与治疗抗性显着相关，但对监测乳腺癌治疗反应的影响有限。在这篇综述中，我们关注乳腺癌治疗中的代谢变化及其评估乳腺癌治疗反应的潜力。我们从癌症病理和遗传差异方面总结了乳腺癌治疗的代谢网络和监管变化，并讨论了代谢成像与各种探针在选择目标受益人进行精准治疗方面的意义。